MedTrace Logo

The Role of Atrial Natriuretic Peptide in the Lipolytic Process: Effect of Obesity and Exercise

NCT02418728 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2016-11-18

No results posted yet for this study

Summary

In the developing countries, obesity prevalence is on a dramatic rise. Obesity is related to co-morbidities and as a result, obesity significantly shortens life expectancy and lowers quality of life. To prevent this, participation in exercise or training programs is absolutely necessary, in order to generate adipose tissue mass loss. The amount of adipose tissue mass loss is, amongst others, dependent on lipolysis which is under endocrine regulation by, mainly, catecholamines, insulin and atrial natriuretic peptide. However, large variations in adipose tissue mass loss and gain are likely in obese subjects, possibly due to a decreased lipolytic effect of these hormones (as was shown for catecholamines in the subcutaneous adipose tissue of obese subjects). However, the relative contribution of atrial natriuretic peptide in the lipolytic process remains elusive, particularly in subjects with obesity, which show an increased plasma expression of atrial natriuretic peptide.

The aim of the present study is to observe the contribution of atrial natriuretic peptide in the subcutaneous adipose tissue of obese subjects. This will be tested by measurements of extracellular glycerol levels (by microdialysis) in the subcutaneous adipose tissue in situ at rest and during endurance exercise under local beta- and alpha-blockade.

Eventually, the knowledge gained from this research will contribute to the optimization of exercise programs for people with obesity.

Conditions

Interventions

OTHER

subcutaneous adipose tissue microdialysis under local beta/alpha blockade

adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis

Sponsors & Collaborators

  • Jessa Hospital

    collaborator OTHER

  • Maastricht University

    collaborator OTHER

  • Hasselt University

    lead OTHER

Principal Investigators

  • Ellen Blaak, prof. dr. · Maastricht University

  • Kenneth Verboven, drs · Hasselt University

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-08-31
Completion
2016-11-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02418728 on ClinicalTrials.gov